Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. - Wikidata - wikimedia - TriplyDB

Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

http://www.wikidata.org/entity/Q37029110

about

Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis A 10-year cohort analysis of routine paediatric ART data in a rural South African setting.Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.Impact of earlier combination antiretroviral therapy on outcomes in children.Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.Insights into Adherence among a Cohort of Adolescents Aged 12-20 Years in South Africa: Reported Barriers to Antiretroviral Treatment.Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol.Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.

P2860

Q21999480-A91B508A-0224-4576-9A94-2D527059CBA4 Q31127942-88486965-C4FF-4364-9AE4-8C97237340BD Q33624953-4FBE1E14-80F4-4F1A-B9FE-3D8630824D82 Q33884183-4D44C1F7-F626-482E-A739-9675398DDDEC Q35599081-2D4327DD-2596-4325-9D99-DCA1B64CA3B7 Q36501872-B0D1901D-8723-4D56-AA27-42EC6E3D0BEC Q36558893-BCDF59B8-BB71-4638-AEC2-C5120A183E77 Q37404721-CE0EBCCA-8CD8-48EC-8464-F6BB45B23037 Q37544710-DA99FBF0-B79A-48C9-B873-41911376171B Q38239183-082A7F4B-40B5-4379-9454-6DE38B89AFC3 Q47548671-F1D70725-1027-41B7-8F96-8BDFAA3113EA

P2860

Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

http://www.wikidata.org/entity/Q37029110

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Poor early virologic performan ...... ens for HIV-infected children.

@en

Poor early virologic performan ...... ens for HIV-infected children.

@nl

type

label

Poor early virologic performan ...... ens for HIV-infected children.

@en

Poor early virologic performan ...... ens for HIV-infected children.

@nl

prefLabel

Poor early virologic performan ...... ens for HIV-infected children.

@en

Poor early virologic performan ...... ens for HIV-infected children.

@nl

P1433

Q37029110-B8F44923-D34A-4942-88FA-D0B061CFE62B

P1476

Q37029110-D825C2AD-8E2F-4E5F-AFD0-C9CC12F6E7E9

P2093

Q37029110-2FAE3F6A-EA7B-421F-94BD-31521BEDA290

Q37029110-7914C716-E572-4E17-B351-F5302494D7BD

Q37029110-806E455F-FC46-49C1-9A0B-A47DE695F797

Q37029110-EE780ED7-8702-4BB3-8722-E0702C286E2A

P2860

Q37029110-007363A6-25A9-43C8-B7BC-D29A5F9CAC08

Q37029110-02221A23-D432-481A-BC1D-8D948ED3D7AA

Q37029110-2B60E720-E5A5-4AA8-87DE-4DA20F0B8C39

Q37029110-3551764E-2B3F-4FE8-927B-81DEAFBEDAD9

Q37029110-4BD8F657-4CF8-4BD9-AF2F-F10F302FF01A

Q37029110-528EA4E1-CEB1-4A5F-A390-A480B5FB46F2

Q37029110-5F286E8E-AB90-4BDD-8C94-F8B0AC401D88

Q37029110-6CA230A4-5D54-4AD3-8E29-D480BF71DBFF

Q37029110-7965FE92-E36D-495D-99D0-6CFEB01BD1B9

Q37029110-800E61FA-D190-4CBE-857E-37AACB37E857

P304

Q37029110-C4638E40-B443-4C97-AD51-FB859E6C986D

P31

Q37029110-5CF5721F-CBCB-4207-90AE-B50E857BF07E

P356

Q37029110-9AA2C744-3F63-4254-ABA3-A4B058BB2EB2

P433

Q37029110-E02C34D9-9960-4106-9319-85D695DDED6C

P478

Q37029110-D0CA67D6-F96E-4CF7-8A0E-641B8F7CA085

P50

Q37029110-00C9166C-2EF3-4722-82F6-920D96AF5E72

Q37029110-0FD4FA61-DD7E-426D-A598-23C48A60C8A8

Q37029110-11AB5D3F-5404-443D-ACB3-DD61717A02A4

Q37029110-405B3C6B-5E52-4DB8-AABD-BC2F206638DA

Q37029110-5558983E-4696-414B-98CD-3C8A075FF0A8

Q37029110-7BE8A392-4549-4692-B30C-B3D55BFE8A47

P577

Q37029110-E21D5371-CBDF-4408-B52D-A3BF5C27816B

P5875

Q37029110-33305EE2-7CAE-4128-8F56-61305B6E79D8

P698

Q37029110-B0B12336-3B94-4ADD-A21C-F6BDFEAC562E

P921

Q37029110-B8A9D0C2-ECEF-44BA-95D0-FA0D62EC2D85

Q37029110-CCDE07FA-E27E-4F47-B0C9-3C5CFB79A297

P932

Q37029110-6041550E-866E-474B-B847-537A276DBC87

P356

INF.0B013E31828C3738

P1433

Pediatric Infectious Disease Journal

P1476

Poor early virologic performan ...... ens for HIV-infected children.

@en

P2093

Erica Lazarus

http://www.w3.org/2001/XMLSchema#string

Gary Reubenson

http://www.w3.org/2001/XMLSchema#string

Gillian Sorour

http://www.w3.org/2001/XMLSchema#string

Karl-Günter Technau

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis

Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

P304

851-855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/INF.0B013E31828C3738

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Karl-Günter Technau

Mary-Ann Davies

Renate Strehlau

Elaine J Abrams

Ashraf Coovadia

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249966249

http://www.w3.org/2001/XMLSchema#string

P698

23860481

http://www.w3.org/2001/XMLSchema#string

P921

P932

3717192

http://www.w3.org/2001/XMLSchema#string